BIOLOGICAL THERAPIES B-DOSE FORTE 2.5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

biological therapies b-dose forte 2.5ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

BIOLOGICAL THERAPIES B-DOSE 2mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

biological therapies b-dose 2ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

BIOLOGICAL THERAPIES IV B-DOSE 2mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

biological therapies iv b-dose 2ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Multivitamin Injection Solution for injection  Vitamin A 2000 IU/ML, Vitamin D3 2000 IU/ML, Vitamin E Acetate 4 MG/ML, Thiamine Hydrochloride 10 MG/ML, Pyridoxine Hydrochloride 5 MG/ML, Riboflavine 0.04 MG/ML, Nicotinamide 10 MG/ML, Vitamin B12 10 MCG/ML, Phosphate Sodium 1 MG/ML, D-Panthenol 1 MG/ML, Tanzania - English - Tanzania Medicinces & Medical Devices Authority

multivitamin injection solution for injection vitamin a 2000 iu/ml, vitamin d3 2000 iu/ml, vitamin e acetate 4 mg/ml, thiamine hydrochloride 10 mg/ml, pyridoxine hydrochloride 5 mg/ml, riboflavine 0.04 mg/ml, nicotinamide 10 mg/ml, vitamin b12 10 mcg/ml, phosphate sodium 1 mg/ml, d-panthenol 1 mg/ml,

bimeda amea limited, - vitamin a , vitamin d3 , vitamin e , thiamine , pyridoxine , riboflavine , vitamin b12 , niacinamide , phosphate sodium , d-panthenol , d-biotin , cal - solution for injection - vitamin a 2000 iu/ml, vitamin d3 2000 iu/ml, vitamin e acetate 4 mg/ml, thiamine hydrochloride 10 mg/ml, pyridoxine hydrochloride 5 mg/ml, riboflavine 0.04 mg/ml, nicotinamide 10 mg/ml, vitamin b12 10 mcg/ml, phosphate sodium 1 mg/ml, d-panthenol 1 mg/ml,

SATISPLEX TABLET Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

satisplex tablet

zontron pharmaceuticals sdn. bhd. - calcium pantothenate; cyanocobalamin; pyridoxine hcl/vitamin b6; riboflavine; thiamine mononitrate; nicotinamide -

SOLUVIT N powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

soluvit n powder for injection vial

fresenius kabi australia pty ltd - sodium ascorbate, quantity: 113 mg (equivalent: ascorbic acid, qty 100 mg); folic acid, quantity: 0.4 mg; pyridoxine hydrochloride, quantity: 4.9 mg (equivalent: pyridoxine, qty 4 mg); nicotinamide, quantity: 40 mg; cyanocobalamin, quantity: 5 microgram; thiamine nitrate, quantity: 3.1 mg; biotin, quantity: 60 microgram; sodium pantothenate, quantity: 16.5 mg (equivalent: pantothenic acid, qty 15 mg); riboflavine sodium phosphate, quantity: 4.9 mg (equivalent: riboflavine, qty 3.6 mg) - injection, powder for - excipient ingredients: edetate sodium; methyl hydroxybenzoate; glycine - soluvit n is intended as a supplement in intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in adults, adolescents, children and infants. fat-soluble vitamins should also be administered to patients receiving prolonged parenteral nutrition.

CERNEVIT multivitamin powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cernevit multivitamin powder for injection vial

baxter healthcare pty ltd - riboflavine sodium phosphate, quantity: 5.67 mg; pyridoxine hydrochloride, quantity: 5.5 mg; cyanocobalamin, quantity: 6 microgram; nicotinamide, quantity: 46 mg; dl-alpha-tocopherol, quantity: 10.2 mg; ascorbic acid, quantity: 125 mg; retinol palmitate, quantity: 3500 iu; colecalciferol, quantity: 5.5 microgram; dexpanthenol, quantity: 16.15 mg; biotin, quantity: 69 microgram; cocarboxylase tetrahydrate, quantity: 5.8 mg (equivalent: thiamine, qty 3.51 mg); folic acid, quantity: 414 microgram - injection, powder for - excipient ingredients: glycine; glycocholic acid; hydrochloric acid; sodium hydroxide; lecithin - cernevit is indicated in adults and children over 11 years of age requiring parenteral multivitamin supplementation to correct or prevent vitamin deficiencies when oral administration is contraindicated, impossible or insufficient. the product does not contain vitamin k, which may be given separately if required.

Eurobio Children"s Multivitamins & Minerals Chewable Tablet Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eurobio children"s multivitamins & minerals chewable tablet

eurobio sdn bhd - biotin; calcium pantothenate; folic acid; vitamin b12 (cyanocobalamin); vitamin c (as ascrobic acid); ferrous fumarate; nicotinamide (as nicotinamide 33.3%); zinc (zinc oxide); vitamin e (dl-alpha tocopheryl acetate); manganese (as manganese sulphate monohydrate); vitamin b2 (riboflavine as riboflavine 33.3%); vitamin b1 (thiamine nitrate as thiamine 33.3%); vitamin b6 (pyridoxine hydrochloride as pyridoxine hydrochloride 33.3%); vitamin a (retinyl palmitate as dry vitamin a palmitate 500); magnesium (as ma -